Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Now Viewing

EP: 1.Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP: 2.Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP: 3.EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP: 4.SOGUG-AUREA Study Overview

EP: 5.SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP: 6.Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP: 7.Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

Related Videos

Related Content

Advertisement

July 25th 2025

Genetic Study Finds Hypothyroidism May Increase PAH Risk

Maggie L. Shaw

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.

Related Content

Advertisement

July 25th 2025

Genetic Study Finds Hypothyroidism May Increase PAH Risk

Maggie L. Shaw

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

July 23rd 2025

Single-Dose Fosfomycin Found as Safe, Effective as Other Antibiotics for Uncomplicated UTIs

Brooke McCormick

Fosfomycin proved to be a safe, effective alternative for treating uncomplicated urinary tract infections (UTIs), potentially reducing antibiotic resistance and costs.